Tanabe Mitsubishi turns product development over to venture company

Mitsubishi Tanabe announced that phase I of its antibody-drug complex MT-8633 against solid cancer will be carried out by Open Innovation Partners, a Tokyo-based venture. It is believed that this move is meant to raise development speed. Tanabe-Mitsubishi Pharma news...

RIKEN team develops novel self-healing polymers

A team at RIKEN’s Center for Environmental Resources Science has developed a precise copolymerization of ethylene and anisylpropylenes by using a proprietary rare earth catalyst. The new polymer exhibits high elongation (2200%) and excellent self-repairing...